Response, progression-free survival, overall survival, time-to-next-treatment, and toxicity outcomes were evaluated among patients with advanced cutaneous squamous cell carcinoma (cSCC) who received first-line treatment with immune checkpoint inhibitors.
The ongoing multicenter open-label adaptively randomized phase 2 I-SPY2 trial is currently investigating dual immune blockade with cemiplimab plus the investigational agent REGN3767 as neoadjuvant therapy for early-stage, high-risk breast cancer, and new data were presented yesterday at the San Antonio Breast Cancer Symposium.
Babytam is the 5-mg daily dose of tamoxifen being studied in the ongoing TAM-01 study, which is investigating incidence of invasive breast cancer or ductal carcinoma in situ among high-risk women who have received the treatment regimen for 3 years.
Infertility and mental health have a complex relationship, with the impact of mental distress in evaluating for infertility and fertility treatments being quite significant.
Mental and physical health aspects of quality of life (QOL) improved after sutimlimab treatment in patients with cold agglutin disease (CAD) during a phase 3 trial.
Patient-reported outcomes (PROs) within breast cancer settings can be instrumental in helping patients feel heard and improving their overall quality of care, said Oluwadamilola "Lola" Fayanju, MD, MA, MPHS, FACS, chief of breast surgery at Penn Medicine.
A retrospective cohort study found that rapid thinning of the ganglion cell complex was associated with central visual field decline.
Tom Robinson, vice president of global access at JDRF, lists 3 pieces of advice for groups looking to create indexes for other conditions similar to the Type 1 Diabetes (T1D) Index.
A cohort study found that chronic kidney disease (CKD) was associated with the development of abdominal aortic aneurysm, with risk increasing as CKD stage advanced.
Abstracts from the American Epilepsy Society (AES) display potential benefits of cannabidiol (CBD) on pediatric patients with epilepsy in tertiary care centers and highlight areas where further research is needed.
Patients exposed to childhood maltreatment were at greater risk for developing atopic disease compared with unexposed counterparts, and risk of atopic dermatitis and allergic rhinoconjunctivitis may have been attentuated by misdiagnosis.
William Jacout, MD, a medical oncologist and researcher at the Institut du Cancer de Montpellier Val d'Aurelle in France, shares what providers should keep in mind when using genomics as a diagnostic and treatment decision-making tool for patients with breast cancer.
A judge blocked the FDA’s mandate that would require cigarette companies to publish a graphic warning on packaging; the Jynneos mpox vaccine effectively offered strong protection against the virus; intense movement was found to reduce the risk of death within 7 years.
The study, based on care in Japan, found patients would be more quickly referred for targeted therapy.
Coverage from the Institute for Value-Based Medicine® event in Denver, Colorado, held October 5, 2022. The event was held in partnership with Rocky Mountain Cancer Centers.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Initial data on NTLA-2001, which is a novel investigative intravenous agent that works to prevent development of cardiac transthyretin (ATTR) amyloidosis by targeting the TTR gene and TTR protein levels, were presented at this year’s American Heart Association’s Scientific Sessions in Chicago.
The utility of annual MRI plus mammogram was investigated in a new meta-analysis delivered at this year’s San Antonio Breast Cancer Symposium, with the goal of optimizing use of MRI by considering potential for overdiagnosis and tailoring to age and risk group.
As they headed home Thursday from the 2022 American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting & Exhibition in Las Vegas, pharmacists pitched in to help a man having a medical emergency aboard a United flight bound for Newark, New Jersey.
A recent review emphasizes a need for novel therapies, summarizes current phase 3 clinical trials, and suggests several considerations for future trials in high-risk myelodysplastic syndromes (MDS).
Human epidermal growth factor receptor 2 (HER2)-low breast disease has a number of new treatments available, and more providers need to be aware of how it differs from other forms of breast cancer, according to Adam Brufsky, MD, PhD, University of Pittsburgh, at the San Antonio Breast Cancer Symposium.
Due to the study’s small sample, further research is needed to understand the role of bromocriptine in reducing blood pressure and artery stiffness in youth with type 1 diabetes (T1D).
The American College of Cardiology’s 71st Scientific Session covered how to address the impact of social determinants of health on cardiovascular outcomes, understanding the latest developments in digital health, and the role of COVID-19 on heart health.
With human epidermal growth factor receptor 2 (HER2)–low breast cancer still a relatively newly classified disease subtype, research is increasingly focused on the disease, in which cells express lower levels of the HER2 protein than are adequate to classify a patient as having HER2-positive disease.
The Sleep 2022 meeting from early June included talks on narcolepsy, the role of race in sleep disturbances, and the use of opioids in restless leg syndrome.
Patients with pemphigus reported lower risk of myocardial infarction and stroke, among other cardiovascular and metabolic outcomes, when treated with rituximab compared with the first-line corticosteroid-sparing agents azathioprine and mycophenolate mofetil.
Approximately 5.5 million people have enrolled in health care coverage through the Affordable Care Act (ACA) marketplace for 2023; the Gavi alliance is debating the end of the worldwide vaccine sharing initiative; the White House is now tracking nonfatal opioid overdoses.
Matthew Zirwas, MD, FAAD, associate professor of dermatology at Ohio University in Athens, Ohio provides updates on treatment options for AD at the 2022 SDPA Fall Conference.
This paper follows the 10-year remission mark for the first child treated with CD19-targeted CAR (chimeric antigen receptor) T-cell therapy for B-cell acute lymphoblastic leukemia (B-ALL), adding promise to the notion that the technology can provide long-term durable remissions in patients who are highly refractory to chemotherapy.
